EBElizabeth Brunk

Elizabeth Brunk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizabeth Brunk has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor–Positive Breast Cancer

    by Austin A. Whitman, Rasha T. Kakati, Santiago Haase, Christine H.N.C. Thai, Surya K. Tripathi, Attila T. Szenasi, Elizabeth C. Brunk, Denis O. Okumu, Michael P. East, Sarahi G. Molina, et al.

    Resistance to endocrine therapy (ET) is common in estrogen receptor–positive (ER+) breast cancer. Multiple studies have demonstrated that upregulation of MAPK signaling pathways contributes to ET resistance. Herein we show that vandetanib treatment suppresses MAPK signaling and enhances sensitivity to ET across ET-sensitive and ET-resistant ER+ cell lines and patient-derived organoids (PDO). Vandetanib treatment reprograms transcription toward a less proliferative, more estrogen-responsive luminal A–like state by enriching ERα chromatin binding at canonical estrogen response elements. Multiplexed kinase inhibitor bead–mass spectrometry revealed kinase network reprogramming, including upregulation of PI3K and HER2 activity, as shared adaptive resistance mechanisms to vandetanib treatment. Cotreatment with the HER2 inhibitor lapatinib further enhanced sensitivity to vandetanib. Using an operating room-to-laboratory short-term ex vivo assay coupled to single-cell RNA sequencing, we demonstrate conserved gene expression changes in primary tumor cells, including increased HER2 activity signatures, following vandetanib treatment. Vandetanib sensitivity signatures were generated from cell line and primary human tumor cells which correlate with vandetanib sensitivity in ER+ PDO and patient-derived xenograft models. Future studies should evaluate whether signatures predict responses in patients with ER+ breast tumors and determine the role of cotargeting HER2 signaling with vandetanib therapy.


  • Open Access

    An open imaging and AI resource enabling unbiased quantification of extrachromosomal DNA at scale

    by Poorya Behnamie, River Summers, Jingting Chen, Aarav Mehta, Adesuwa Igbinigie, Qin Liu, Molly Murray, Damien Guilbaud, Marc Niethammer, Elizabeth Brunk

    Quantitative imaging of extrachromosomal DNA (ecDNA) is increasingly important for studying cancer heterogeneity and adaptation, yet automated analysis has been limited by the absence of accessible imaging data, gold standard annotations and adaptable computational tools. Here we establish an open resource for computational ecDNA imaging, integrating 2,986 native-resolution metaphase FISH image sets with manual annotations, standardized benchmarks and open-source quantification frameworks. We use this resource to systematically compare existing and newly developed approaches spanning rule-based computer vision, deep-learning-based segmentation and probabilistic localization. This comparison reveals count-dependent underestimation that distorts ecDNA copy-number distributions and motivates ecCount, a probabilistic localization method developed here to preserve individual ecDNA signals and quantitative burden. ecCount achieves an object-level F1 score of 0.939 on held-out images with minimal count bias. Together, the images, annotations, retrainable models, evaluation tools and guided workflows provide community infrastructure for applying, adapting and improving automated ecDNA quantification across experimental systems.

  • Python-Based Interactive Notebooks for Teaching AI and Data Science to Undergraduate Students in the Life Sciences

    by Kriti Shukla, Elizabeth Brunk

    This chapter presents a reproducible, cloud-based framework for integrating Python-driven data analysis into a large-enrollment undergraduate biochemistry course. Rapid growth in technologies has transformed biochemistry into a data-intensive discipline, yet most life-science students receive little formal training in computational skills. To address this gap, we developed a set of interactive Jupyter notebooks that embed introductory coding, protein structure visualization, metabolic modeling, and simple multi-omics analysis directly within the core biochemistry curriculum. The workflow is delivered entirely through the CyVerse Discovery Environment, which provides browser-based JupyterLab sessions with preconfigured Python environments, version-controlled notebooks, and standardized datasets. This infrastructure eliminates the need for local installation, supports hundreds of simultaneous users, and ensures consistent execution across diverse student hardware. The notebooks follow a scaffolded learn-apply-reflect design that links biochemical concepts with incremental coding tasks, enabling students with no prior experience to manipulate real datasets, generate visualizations, and interpret quantitative patterns. Assessment using validated pre/post surveys across more than 1000 matched responses demonstrated substantial gains in students’ confidence with coding and their ability to interpret omics data. The protocol outlined here offers a scalable, equitable model for incorporating computational literacy into biochemistry education and can be readily adapted for related life-science courses.

  • Open Access

    STARMAP: A 3D-informed framework for mapping functional regions in proteins to regulatory and cellular phenotypes

    by Kriti Shukla, Jonnathan Castro, Darby Cheng, Lucy Holley, Elizabeth Brunk

    Artificial Intelligence (AI) has transformed biology by revealing patterns in large-scale datasets and predicting regulatory relationships. Yet even the most advanced models often fail to identify biologically meaningful mechanisms from statistical associations. This limitation arises not from algorithmic capacity but from the lack of mechanistically grounded input features. Our structure-informed framework Structure-based Topological Analysis of Regulatory and Molecular Activity Patterns (STARMAP) embeds protein three-dimensional structure and population-scale functional genomics data into a unified representation for mechanistic inference. By mapping over 1.5 million naturally occurring variants across ∼1,700 cancer cell lines onto protein structures, STARMAP was able to identify spatial clusters of variation associated with shifts in transcriptional regulatory networks and drug response phenotypes. This approach transforms natural genetic variation into a large-scale, structure-informed screen, enabling systematic discovery of regulatory relationships across the proteome and providing interpretable and testable models of cellular regulation.

  • Open Access

    Extrachromosomal DNA Gives Cancer a New Evolutionary Pathway

    by Elizabeth Brunk, Yue Wang, Oliver Cope, Jingting Chen, Aarav Mehta, Dalia Fleifel, Christina Gutierrez-Ford, Poorya Benhamie, Santiago Haase, Saygin Gulec, et al.

    During tumor progression, it has been assumed that individual cells that have acquired advantageous mutations overtake the population. Cancers driven by extrachromosomal DNA (ecDNA) do not follow this paradigm. Instead, these tumors have a spectrum of oncogene copy numbers across cells, and graded ecDNA variation may function as a form of bet-hedging that equips tumors with a broad range of phenotypes. Using imaging, single-cell multiomics, and multiplexed proteomics, we systematically characterized ecDNA levels across thousands of single cells. Higher ecDNA dosage produces proportional changes in transcript abundance, chromatin accessibility, protein levels, cell-cycle progression, and proliferation. Genes amplified on ecDNA exhibit distinct transcriptional scaling regimes that shift when the same genes are reintegrated into chromosomal homogeneous staining regions. When we experimentally disrupted the continuum of ecDNA dosage by sorting cells into low- and high-copy number states, the population rapidly recovered its original, continuous distribution. Our time-course data, live-cell imaging, and stochastic models collectively show that restoring this spectrum is an active, deterministic process rather than the passive outcome of random segregation. Together, these findings position ecDNA-mediated expression as a distinct evolutionary mechanism that endows tumors with rapid, population-level adaptability. These findings offer insight into why ecDNA-driven cancers are among the most aggressive and treatment-resistant.


  • Open Access

    Decoding drug-responsive cell subpopulations in triple-negative breast cancer using single-cell multiomics

    by Yue Wang, Santiago Haase, Austin Whitman, Adriana S. Beltran, Philip M. Spanheimer, Elizabeth Brunk


  • Open Access

    AI ‐Driven Variant Annotation for Precision Oncology in Breast Cancer

    by Kriti Shukla, Yue Wang, Philip M. Spanheimer, Elizabeth Brunk

    Interpreting the functional impact of genomic variants remains a major challenge in precision oncology, particularly in breast cancer, where many variants of unknown significance lack clear therapeutic guidance. Current annotation strategies focus on frequent driver mutations, leaving rare or understudied variants unclassified and clinically uninformative. Here, we present an Artificial Intelligence/Machine Learning (AI/ML)‐driven framework that systematically identifies variants associated with key breast cancer phenotypes, including ESR1 and EZH2 activity, by integrating genomic, transcriptomic, structural, and drug response data. Using CCLE/DepMap and TCGA datasets, we analyzed > 12,000 variants across breast cancer genomes, identifying structurally clustered mutations that share functional consequences with well‐characterized oncogenic drivers. This approach reveals that mutations in PIK3CA, TP53, and other genes strongly associate with ESR1 signaling, challenging conventional assumptions about endocrine therapy response. Additionally, EZH2‐associated variants emerge in unexpected genomic contexts, suggesting new targets for epigenetic therapies. By shifting from frequency‐based to structure‐informed classification, we expand the set of potentially actionable mutations, enabling improved patient stratification and drug repurposing strategies. This work provides a scalable, clinically relevant method to accelerate variant annotation, offering new insights into drug sensitivity and resistance mechanisms. Future validation efforts will refine these predictions and integrate clinical outcomes to guide personalized treatment strategies. Our findings highlight the transformative potential of AI/ML in redefining cancer variant interpretation, bridging the gap between genomics, functional biology, and precision medicine.


  • Open Access

    Extrachromosomal DNA Gives Cancer a New Evolutionary Pathway

    by Yue Wang, Oliver Cope, Jingting Chen, Aarav Mehta, Dalia Fleifel, Christina G. Ford, Poorya Behnamie, Molly Murray, Santiago Haase, Saygin Gulec, et al.

    During tumor progression, it has been assumed that individual cells that have acquired advantageous mutations overtake the population. Cancers driven by extrachromosomal DNA (ecDNA) do not follow this paradigm. Instead, these tumors have a spectrum of oncogene copy numbers across cells, and graded ecDNA variation may function as a form of bet-hedging that equips tumors with a broad range of phenotypes. Using imaging, single-cell multiomics, and multiplexed proteomics, we systematically characterized ecDNA levels across thousands of single cells. Higher ecDNA dosage produces proportional changes in transcript abundance, chromatin accessibility, protein levels, cell-cycle progression, and proliferation. Genes amplified on ecDNA exhibit distinct transcriptional scaling regimes that shift when the same genes are reintegrated into chromosomal homogeneous staining regions. When we experimentally disrupted the continuum of ecDNA dosage by sorting cells into low- and high-copy number states, the population rapidly recovered its original, continuous distribution. Our time-course data, live-cell imaging, and stochastic models collectively show that restoring this spectrum is an active, deterministic process rather than the passive outcome of random segregation. Together, these findings position ecDNA-mediated expression as a distinct evolutionary mechanism that endows tumors with rapid, population-level adaptability. These findings offer insight into why ecDNA-driven cancers are among the most aggressive and treatment-resistant.


  • Open Access

    AI-Driven Variant Annotation for Precision Oncology in Breast Cancer

    by Kriti Shukla, Yue Wang, Philip M. Spanheimer, Elizabeth Brunk

    Interpreting the functional impact of genomic variants remains a major challenge in precision oncology, particularly in breast cancer, where many variants of unknown significance (VUS) lack clear therapeutic guidance. Current annotation strategies focus on frequent driver mutations, leaving rare or understudied variants unclassified and clinically uninformative. Here, we present an AI/ML-driven framework that systematically identifies variants associated with key breast cancer phenotypes, including ESR1 and EZH2 activity, by integrating genomic, transcriptomic, structural, and drug response data. Using DepMap and TCGA datasets, we analyzed >12,000 variants across breast cancer genomes, identifying structurally clustered mutations that share functional consequences with well-characterized oncogenic drivers. This approach reveals that mutations in PIK3CA, TP53, and other genes strongly associate with ESR1 signaling, challenging conventional assumptions about endocrine therapy response. Additionally, EZH2-associated variants emerge in unexpected genomic contexts, suggesting new targets for epigenetic therapies. By shifting from frequency-based to structure-informed classification, we expand the set of potentially actionable mutations, enabling improved patient stratification and drug repurposing strategies. This work provides a scalable, clinically relevant method to accelerate variant annotation, offering new insights into drug sensitivity and resistance mechanisms. Future validation efforts will refine these predictions and integrate clinical outcomes to guide personalized treatment strategies. Our findings highlight the transformative potential of AI/ML in redefining cancer variant interpretation, bridging the gap between genomics, functional biology, and precision medicine. Study Highlights: Current Knowledge: Breast cancer treatment decisions are increasingly guided by genomic profiling, yet most clinical actionability is based on frequent driver mutations (e.g., PIK3CA, TP53, ESR1). Many variants of unknown significance (VUS) remain unclassified, and current annotation methods are slow, relying on manual curation or low-throughput assays, leaving rare mutations uncharacterized. Study Focus: This study applies AI/ML-driven variant annotation to systematically identify mutations that drive key breast cancer phenotypes, such as ESR1 and EZH2 activity, beyond currently known mutations. By using structural and functional clustering, we assess whether rare and understudied mutations can be prioritized for clinical relevance. Key Findings: ● Analyzed >12,000 variants across breast cancer genomes, integrating multi-omic and structural data. ● Identified strong ESR1-associated mutations in PIK3CA, TP53, and other genes, expanding the landscape of actionable mutations. ● Discovered EZH2-associated variants in unexpected contexts, revealing potential epigenetic therapy targets. ● Demonstrated that spatial clustering of mutations within proteins predicts functional consequences, even for rare mutations. Clinical and Translational Impact: ● Scalable AI-powered framework accelerates variant annotation and functional classification. ● Enables faster identification of actionable mutations and improves patient stratification for targeted therapies. ● Provides a data-driven approach to refine clinical trial design, expanding therapy options for patients lacking clear genomic-based treatment guidance.


  • Open Access

    A Multimodal Framework to Uncover Drug-Responsive Subpopulations in Triple-Negative Breast Cancer

    by Yue Wang, Santiago Haase, Austin Whitman, Adriana Beltran, Philip M. Spanheimer, Elizabeth Brunk

    Understanding how individual cancer cells adapt to drug treatment is a fundamental challenge limiting precision medicine cancer therapy strategies. While single-cell technologies have advanced our understanding of cellular heterogeneity, efforts to connect the behavior of individual cells to broader tumor drug responses and uncover global trends across diverse systems remain limited. There is a growing availability of single-cell and bulk omics data, but a lack of centralized tools and repositories makes it difficult to study drug response globally, especially at the level of single-cell adaptation. To address this, we present a multimodal framework that integrates bulk and single-cell treated and untreated transcriptomics data to identify drug responsive cell populations in triple-negative breast cancer (TNBC). Our framework leverages population-scale bulk transcriptomics data from TNBC samples to define seven main “identities”, each representing unique combinations of biologically relevant genes. These identities are dynamic and trackable, allowing us to map them onto single cells and uncover global patterns of how cell populations respond to drug treatment. Unlike static classifications, this approach captures the evolving nature of cellular states, revealing that a select few identities dominate and drive population-level responses during treatment. Crucially, our ability to decode these trends through the inherent noise of single-cell data provides a clearer picture of how heterogeneous cell populations adapt to therapy. By identifying the dominant identities and their dynamics, we can better predict how entire tumors respond to treatment. This insight is essential for designing precise combination therapies tailored to the unique heterogeneity of patient tumors, addressing the single-cell variations that ultimately determine therapeutic outcomes.